"id","description","label","uuid:ID","instanceType","name","rationale"
"StudyDesign_1","The main design for the study","","245a09f8-e04a-402c-8a88-8c9a338d4bdb","StudyDesign","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
